49 results
Page 2 of 3
6-K
EX-4.2
lpwsxkg3kh
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
424B5
khbg6x
8 Sep 20
Prospectus supplement for primary offering
7:31am
6-K
EX-99.1
mqd1c3ts irv
4 Jun 20
ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis
6:11am
F-3
mbfxbc5krh9neln
7 Aug 19
Shelf registration (foreign)
8:24am
F-3
EX-4.1
7b0wua2 f7pos
7 Aug 19
Shelf registration (foreign)
8:24am
F-3
EX-4.2
cvb4vkp684fr
7 Aug 19
Shelf registration (foreign)
8:24am
424B5
qcv51 bxd4ou0j7b00
7 Aug 19
Prospectus supplement for primary offering
8:18am
6-K
EX-99.1
h4lmcyb3t275
7 Aug 19
Current report (foreign)
7:21am
6-K
EX-3.1
h27 gc7lg
20 May 19
Current report (foreign)
5:28pm
6-K
o7c4m3f5yfvq7
28 Sep 18
Current report (foreign)
8:40am
424B5
em4bkx963q
20 Jun 18
Prospectus supplement for primary offering
5:32pm
424B5
52gt5m1zm1spnu6
18 Jun 18
Prospectus supplement for primary offering
9:15pm
6-K
EX-99.1
lj6yu1f7wt7iv xtftrk
18 Jun 18
ObsEva SA Achieves Primary and Secondary Endpoints for EDELWEISS
9:17am
6-K
fnainjk
7 Jun 17
Current report (foreign)
12:00am
20-F
u7zla3olwz68rt04fu
21 Apr 17
Annual report (foreign)
12:00am
F-1
EX-3.2
wprpbl
30 Dec 16
Registration statement (foreign)
12:00am